|
|
 |
| |
Shareholder Information |
THE ACTELION ANNUAL REPORT 2004 |
|
|
|
| |
|
|
|
|
|
|
| Share price |
| |
The following table shows the reported high and low quarterly closing share price of the Actelion shares on the SWX Main Market during the year 2004.
|
|
|
| |
| |
|
| | | High | | Low | |
| First Quarter | | 156 | | 127 | |
| Second Quarter | | 150 | | 130.75 | |
| Third Quarter | | 143.75 | | 106.5 | |
| Fourth Quarter | | 153 | | 98.95 | |
|
|
| |
|
|
|
|
|
|
On 31 December 2004 the last reported closing share price was CHF 116.8 and market capitalization of Actelion Ltd was CHF 2.59 billion, compared with a share price of CHF 133.5 and market capitalization of CHF 2.90 billion the previous year. The total number of registered shareholders on 31 December 2004 was 5631.
|
|
|
| |
|
|
|
|
|
|
| Listing |
| |
Actelion Ltd is organized under Swiss law and is the holding company of the Actelion Group. The company’s initial equity funding was provided in 1998 and 1999 in two separate rounds of financing totaling CHF 66 million.
The registered shares of Actelion Ltd have been listed on the SWX New Market since April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company’s Initial Public Offering at the price of CHF 260 per share raising CHF 246.1 million. On June 20, 2001, Actelion Ltd announced a 4:1 split in its shares.
On September 9th, 2002 Actelion listed the company’s registered shares on the SWX Main Market. The SWX Swiss Exchange waived the requirement for a listing prospectus. The trading symbol remains the same and the company will continue to report full quarterly figures.
|
|
|
| |
| |
|
| Investor Relations Calendar 2005 | |
| February 24 | | Media/Analyst Conference | |
| April 14 | | Annual General Meeting of Shareholders | |
| April 28 | | Q1 2005 Results | |
| July 28 | | Half Year 2005 Results | |
| October 27 | | Nine months 2005 Results | |
|
|
| |
|
|
|
|
|
|
| Board of Directors |
| |
Werner Henrich
Chairman, Basilea Pharmaceutica
Fred J. Meyer
Retired Vice Chairman, Omnicom Group
André J. Mueller
Former Chief Financial Officer
Jean-Paul Clozel
Founder, Chief Executive Officer
Robert E. Cawthorn Chairman
Retired Chairman and CEO, Rhône-Poulenc-Rorer
Jean Malo
Chief Investment Officer, Breeco Management L.P.
Armin Kessler
Former Chief Operating Officer, F. Hoffmann-La Roche
|
|
|
| |
|
|
|
|
|
|
| Scientific Advisory Board |
| |
Joël Ménard
Professor of Public Health, University Pierre et Marie Curie, Paris
Donald Hilvert
Professor of Chemistry at the Swiss Federal Institute of Technology (ETH), Zürich
Richard Tsien
Professor of the Department of Molecular and Cellular Physiology, Stanford University, Palo Alto
Craig Pratt
Professor of Medicine and Cardiology, Baylor College of Medicine, Houston
|
|
|
| |
|
|
|
|
|
|
| Business Executive Board |
| |
Jean-Paul Clozel
Founder, Chief Executive Officer
Simon Buckingham
President, Head of US, Canada, Asia Pacific
Isaac Kobrin
Senior Vice President, Head of Clinical Development
Andrew J. Oakley
Vice President, Chief Financial Officer
Christian Chavy
President, Head of Europe, Middle East, Latin America
Louis de Lassence
Vice President, Head of Corporate Services
Satoshi Tanaka
President and Representative Director, Japan
|
|
|
| |
|
|
|
|
|
|
| Senior Management |
| |
Frédéric Bodin
Senior Vice President, Head of International Medical Marketing
Martine Clozel
Senior Vice President, Head of Drug Discovery, Pharmacology & Preclinical Development
Walter Fischli
Founder, Senior Vice President, Head of Drug Discovery, Molecular Biology & Biochemistry
|
|
|
|
